解禁即減持！5天暴漲68%後，廣康生化閃崩
在創新藥概念股一路高歌、市場情緒高漲之際，主營農藥業務的廣康生化也沾光成爲市場追捧的“黑馬”，短短五個交易日股價飆升68%。
然而，在股價剛創下上市以來新高的當口，公司一紙公告引發股價震動——股東集體出手減持，今日開盤公司股價應聲下挫，截止發稿跌超12%。
股東爲何急於套現？
6月3日晚，廣康生化連發兩則公告，一條是持股5%以上股東減持，一條是特定股東減持。
根據公告披露信息，兩類股東計劃同步減持，減持原因均爲“自身資金需求”。
一方面，公司持股5.6757%股東共青城瑞宏凱銀壹號股權投資基金合夥企業(有限合夥)計劃減持公司股份不超過222萬股，即不超過公司總股本的3.00%。
另一方面，共青城華拓至盈貳號投資合夥企業(有限合夥)等4家“華拓系”股東計劃合計減持公司股份不超過222萬股，即不超過公司總股本的3%。
兩波股東合計擬減持比例上限高達6%，減持股份均來源於首次公開發行（IPO）前的股份，剛剛解禁不久。此次也是解禁後首次有股東減持。
值得注意的是，這些股東的減持計劃宣佈得恰逢其時——廣康生化股價剛剛因“蹭熱點”翻倍上漲。從結果看，這波減持可謂踩點精確，這也使得市場質疑聲四起。
儘管減持理由被籠統歸結爲“自身資金需求”，但公告一出，市場立刻作出負面反饋。
上市後業績表現
資料顯示，廣康生化成立於2003年，是一家主營農藥原藥、中間體及製劑的研發、生產和銷售的企業，是廣東省內重要的國家定點農用化學品生產企業。公司於2023年6月在創業板上市。
然而，上市後業績表現疲軟，2023年營收下滑25%，淨利潤和扣非淨利潤分別下降68%和73%。2024年營收有所恢復同比大增46.15%，但扣非淨利潤繼續下滑11.45%。
2025年第一季度，公司營收同比增5.16%，但淨利潤和扣非淨利潤分別下降3%和9.6%。
在基本面並無明顯改善的背景下，近期的股價暴漲更多依賴市場對於“農藥+創新藥”疊加邏輯的炒作預期，而非公司自身經營質量的實質提升。
前十大股東中，2025年一季報顯示，蔡丹羣、蔡紹欣父子依然穩居前兩大股東，持股數量分別爲2582萬股和1568萬股，佔比分別爲34.89%和21.19%，未發生變化。
2024年年報中排名第10的“華泰證券資管-1號員工持股計劃”已退出前十大。取而代之的是張賽雯，新進成爲第10大股東，持股42.8萬股，佔比0.58%。
深圳市華拓至遠貳號投資企業和廣州佳誠十四號創投基金均在2024年減持，分別減持了13.79萬股和7.4萬股，佔比分別下滑0.18%、1.00%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
